Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting
October 07 2019 - 7:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that Todd C. Brady, M.D., Ph.D., President and CEO of
Aldeyra, will present on Thursday, October 10 at the Ophthalmology
Innovation Summit (OIS) at the American Academy of Ophthalmology
2019 Annual Meeting. The presentation will highlight the company’s
Phase 3 ocular programs, which target unmet medical needs for dry
eye disease, allergic conjunctivitis, and proliferative
vitreoretinopathy.
“Based on substantial clinical evidence, we believe that our
Phase 3 programs represent a potential paradigm shift in the
treatment of immune-mediated ocular diseases,” Dr. Brady said. “We
look forward to discussing our lead product candidates with
physicians, clinicians, and researchers at OIS, and continuing to
execute our innovative Phase 3 clinical development plans.”
Details of the presentation
Date: Thursday, October 10, 2019
Time: 9:29 – 9:36 a.m. PDT
Venue: Hilton San Francisco Union
Square
The slides for this event can be viewed and downloaded at
https://ir.aldeyra.com/events on the morning of the presentation. A
video of the presentation will be available approximately two weeks
after the event at https://ois.net/ and
https://ir.aldeyra.com/events. After the video is made available,
it will remain archived on the Aldeyra Therapeutics website for one
year.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to
developing and commercializing next-generation medicines to improve
the lives of patients with immune-mediated diseases. Aldeyra's lead
investigational drug product candidates are first-in-class
potential treatments in development for dry eye disease, allergic
conjunctivitis, proliferative vitreoretinopathy, and
Sj�gren-Larsson Syndrome. The company is also developing other
product candidates for retinal and systemic inflammatory
diseases.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding Aldeyra's strategy, future
operations, future financial position, projected costs and
expenses, prospects, plans, and objectives and Aldeyra's plans and
expectations for its product candidates, including plans relating
to current or future clinical development. Aldeyra intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. In some cases, you can identify
forward-looking statements by terms such as, but not limited to,
"may," "might," "will," "objective," "intend," "should," "could,"
"can," "would," "expect," "believe," "anticipate," "project,"
"target," "design," "estimate," "predict," "potential," "aim,"
"plan" or the negative of these terms, and similar expressions
intended to identify forward-looking statements. Such
forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions and
uncertainties. Aldeyra is at an early stage of development and may
not ever have any products that generate significant revenue. All
of Aldeyra's development timelines may be subject to adjustment
depending on recruitment rate, regulatory review, preclinical and
clinical results, and other factors that could delay the initiation
or completion of clinical trials. Important factors that could
cause actual results to differ materially from those reflected in
Aldeyra's forward-looking statements include, among others, the
timing of enrollment, commencement and completion of Aldeyra's
clinical trials, the timing and success of preclinical studies and
clinical trials conducted by Aldeyra and its development partners;
updated or refined data based on Aldeyra's continuing review and
quality control analysis of clinical data, Aldeyra's ability to
design clinical trials with protocols and endpoints acceptable to
applicable regulatory authorities; delay in or failure to obtain
regulatory approval of Aldeyra's product candidates; the ability to
maintain regulatory approval of Aldeyra's product candidates, and
the labeling for any approved products; the risk that prior
results, such as signals of safety, activity or durability of
effect, observed from preclinical or clinical trials, will not be
replicated or will not continue in ongoing or future studies or
trials involving Aldeyra's product candidates; the scope, progress,
expansion, and costs of developing and commercializing Aldeyra's
product candidates; uncertainty as to Aldeyra’s ability to
commercialize (alone or with others) Aldeyra's product candidates
following regulatory approval, if any; the size and growth of the
potential markets and pricing for Aldeyra's product candidates and
the ability to serve those markets; Aldeyra's expectations
regarding Aldeyra's expenses and revenue, the sufficiency or use of
Aldeyra's cash resources and needs for additional financing; the
rate and degree of market acceptance of any of Aldeyra's product
candidates; Aldeyra's expectations regarding competition; Aldeyra's
anticipated growth strategies; Aldeyra's ability to attract or
retain key personnel; Aldeyra’s limited sales and marketing
infrastructure; Aldeyra's ability to establish and maintain
development partnerships; Aldeyra’s ability to successfully
integrate acquisitions into its business; Aldeyra's expectations
regarding federal, state and foreign regulatory requirements;
regulatory developments in the United States and foreign countries;
Aldeyra's ability to obtain and maintain intellectual property
protection for its product candidates; the anticipated trends and
challenges in Aldeyra's business and the market in which it
operates; and other factors that are described in the "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Aldeyra's Annual
Report on Form 10-K for the year ended December 31, 2018 and
Aldeyra's Quarterly Report on Form 10-Q for the quarter ended June
30, 2019, which are on file with the Securities and Exchange
Commission (SEC) and available on the SEC's website at www.sec.gov.
Additional factors may be set forth in those sections of Aldeyra's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2019, expected to be filed with the SEC in the fourth quarter of
2019.
In addition to the risks described above and in Aldeyra's other
filings with the SEC, other unknown or unpredictable factors also
could affect Aldeyra's results. No forward-looking statements can
be guaranteed and actual results may differ materially from such
statements. The information in this release is provided only as of
the date of this release, and Aldeyra undertakes no obligation to
update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191007005457/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024